A Study of PRT811 in Participants With Advanced Solid Tumors, CNS Lymphoma and Gliomas

Prelude Therapeutics Incorporated86 enrolled

Overview

This is a Phase 1 dose-escalation study of PRT811, a protein arginine N-methyltransferase (PRMT) 5 inhibitor, in subjects with advanced cancers and high-grade gliomas who have exhausted available treatment options. The purpose of this study is to define a safe dose and schedule to be used in subsequent development of PRT811.

This is a multicenter, open-label, dose-escalation, dose-expansion Phase 1 study of PRT811, a PRMT5 inhibitor, in subjects with advanced cancers without any approved or available treatment options including solid tumors, CNS lymphoma, and /or high-grade gliomas. The study will consist of 2 parts, a dose escalation part evaluating subjects with advanced solid tumors, CNS lymphoma, and/or high-grade glioma and a cohort expansion part which will evaluate the safety and efficacy of PRT811 in subjects with advanced solid tumors, and glioblastoma multiforme. For subjects, the study will include a screening phase, a treatment phase, and a post treatment follow-up phase. An end-of-study visit will be conducted within 30 days after the last dose of PRT811.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Advanced Solid Tumor Recurrent Glioma

Interventions

PRT811DRUG

PRT811 will be administered orally

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Malignancies that are refractory to or intolerant of established therapies known to provide clinical benefit for the malignancy in question, or in the opinion of the Investigator, not be a candidate for such therapies * Subjects must have recovered from the effects of any prior investigational system therapies * For subjects with recurrent high-grade glioma or GBM, must have biopsy proven evidence (WHO Grade III or IV) and received external bean fractionated radiotherapy and at least 2 cycles of adjuvant temozolomide chemotherapy. Mutant Glioma must comply with biomarker defined enrollment criterias. * For biomarker-selected solid tumors: must meet enrollment criteria * Eastern Cooperative Oncology Group (ECOG) Performance Score of 0 or 1 * Adequate organ function (bone marrow, hepatic, renal, cardiovascular) * Female subjects of childbearing potential must have a negative pregnancy test within 7 days of the start of treatment and must agree to use an effective method of contraception during the trial Exclusion Criteria: * Untreated concurrent malignancies or malignancies that have been in complete remission for less than one year * Treatment with strong inhibitors of CYP3A4 for which there are no therapeutic substitutions * Inflammatory disorders of the gastrointestinal tract, or subjects with GI malabsorption * HIV positive; known active hepatitis B or C * Known hypersensitivity to any of the components of PRT811

Locations (11)

Sarah Cannon Research Institute at HealthONE

Denver, Colorado, United States

Yale- New Haven Hospital- Yale Cancer Center

New Haven, Connecticut, United States

Christiana Care Health Services, Christiana Hospital

Newark, Delaware, United States

Outcomes

Primary Outcomes

To describe dose limiting toxicities (DLT) of PRT811

Dose limiting toxicities will be evaluated through the first cycle

Time frame: Baseline through Day 21

To determine the maximally tolerated dose (MTD)

The MTD will be established for further investigation in participants with solid tumors and gliomas

Time frame: Baseline through approximately 2 years

To determine the recommended phase 2 dose (RP2D) and schedule of PRT811

The RP2D will be established for further investigation in participants with solid tumors and gliomas

Time frame: Baseline through approximately 2 years

Secondary Outcomes

To describe the adverse event profile and tolerability of PRT811

Adverse events as characterized by type, frequency, severity, timing, seriousness and relationship to study therapy

Time frame: Baseline through approximately 2 years

To describe the pharmacokinetic profile of PRT811

PRT811 pharmacokinetics will be calculated including the maximum observed plasma concentration

Time frame: Cycle 1 (each cycle is 21 days) on Days 1, 8 and 14. For subsequent cycles, Day 1 of each cycle through the end of study treatment, an average of 6 months

To describe any anti-tumor activity of PRT811

Anti-tumor activity of PRT811 will be based on the measurement of objective responses

Time frame: Baseline through approximately 2 years

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.